Clinical trials: Phase 2
Multiple Sclerosis Spasticity
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity
- Trial name
- MSS (NCT06782490)
- Testing
- BMS-986368
- Where
- 61 sites in United States, Australia and 5 more
- Volunteers
- 200 people
- Sponsor
- Celgene
Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
This is a phase II, multicenter, open-label trial evaluating the safety and efficacy of pacritinib and selinexor in JAK inhibitor naïve patients with anemia and thrombocytopenia.
- Conditions
- Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- NCT07447817
- Testing
- Pacritinib, Selinexor
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- John Mascarenhas
Substance Use Disorders, Substance Use
Ketamine for Methamphetamine Use Disorder
This study aims to determine whether treatment response with IV ketamine is superior to treatment response with IV midazolam in adults with moderate to severe MUD.
- Conditions
- Substance Use Disorders, Substance Use, Methamphetamine Abuse
- Trial name
- KMD (NCT06496750)
- Testing
- Ketamine Hydrochloride, Midazolam Hydrochloride
- Where
- 5 sites in United States
- Volunteers
- 120 people
- Sponsor
- University of Texas Southwestern Medical Center
Radiation of Neurocranial Region
Enhancement of Neurocognitive Functions by Hippocampal Sparing Radiotherapy
This randomized trial examines possible enhancements in live quality and neurocognitive functions in patients after radiotherapy of the neurocranial area with hippocampal sparing.
- Trial name
- HIPPO-SPARE 01 (NCT01849484)
- Testing
- Radiation according to indication with hippocampal sparing, Radiation according to indication without hippocampal protection
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Friedreich Ataxia
An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia
An open label study designed to evaluate the safety, PK, PD, and clinical effects of long-term daily administration of CTI-1601 enrolling adolescent and adult patients with FRDA who have participated in a prior clinical study of…
- Trial name
- NCT06447025
- Testing
- CTI-1601
- Where
- 10 sites in United States
- Volunteers
- 85 people
- Sponsor
- Larimar Therapeutics, Inc.
Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma
DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
This study is open to adults with advanced small cell lung cancer and other neuroendocrine cancers. The study has 2 parts. The purpose of Part 1 is to find a suitable dose of a combination study treatment, obrixtamig and ZL-1310.
- Conditions
- Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology, Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology
- Trial name
- NCT07707895
- Testing
- Obrixtamig, ZL-1310, Atezolizumab
- Where
- 27 sites in United States, Australia and 9 more
- Volunteers
- 60 people
- Sponsor
- Boehringer Ingelheim
Invasive Mould Infection
Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy
The purpose of this study is to determine if EL219 is safe and effective compared to liposomal amphotericin B (LAmB) or voricanozole for early treatment of invasive mould infections
- Trial name
- NCT07215273
- Testing
- EL219, Active Comparator- IV Antifungal (LAmB or voriconazole)
- Where
- 30 sites in United States, Belgium and 4 more
- Volunteers
- 60 people
- Sponsor
- Elion Therapeutics, Inc.
Depressive Disorder, Major, Inflammation
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
This study is a mechanistic randomized controlled trial that investigates whether inhibition of tumor necrosis factor signaling via intravenous infusion of infliximab improves psychomotor speed and executive functioning in…
- Trial name
- NCT06136546
- Testing
- Infliximab
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Massachusetts General Hospital
Colorectal Cancer (CRC)
Toripalimab Plus Cetuximab and Irinotecan for Second-Line Right-Sided RAS/BRAF Wild-Type Advanced Colon Cancer Phase II Study
This phase II, single-arm clinical study aims to evaluate the efficacy and safety of toripalimab combined with cetuximab and irinotecan as second-line treatment for patients with advanced right-sided colon cancer with wild-type…
- Trial name
- NCT07896681
- Testing
- Toripalimab, Cetuximab, Irinotecan
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Low-grade NMIBC, FGFR Gene Amplification
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC
- Conditions
- Low-grade NMIBC, FGFR Gene Amplification, FGFR Gene Alterations, FGFR3 Gene Alteration
- Trial name
- SURF302 (NCT06995677)
- Testing
- TYRA-300 60mg, TYRA-300 50mg, TYRA-300 Dose 70 mg
- Where
- 48 sites in United States, Australia and 2 more
- Volunteers
- 90 people
- Sponsor
- Tyra Biosciences, Inc
B Acute Lymphoblastic Leukemia
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia…
- Trial name
- NCT06124157
- Testing
- Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy
- Where
- 161 sites in United States, Australia and 2 more
- Volunteers
- 222 people
- Sponsor
- National Cancer Institute (NCI)
Liver Cancer, Intrahepatic Cholangiocarcinoma
REGULUS: MRI-guided Adaptive SABR for Liver Cancers
Single arm unblinded study of simulation-free MRI-guided SABR with adaptive replanning in one session for treatment of patients with liver cancers
- Conditions
- Liver Cancer, Intrahepatic Cholangiocarcinoma, Liver Metastases, HCC
- Trial name
- NCT07223307
- Testing
- MRI-guided adaptive stereotactic ablative body radiotherapy (SABR)
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Stanford University
Doxorubicin Induced Cardiotoxicity, Doxorubicin Induced Cardiomyopathy
The Impact of Using Nicorandil for the Prevention of Doxorubicin-Induced Cardiotoxicity
Breast cancer is one of the world's most common cancers in females. Most of the chemotherapy protocols used to treat breast cancer involve doxorubicin. Doxorubicin has a very significant antitumor effect on breast tumors.
- Conditions
- Doxorubicin Induced Cardiotoxicity, Doxorubicin Induced Cardiomyopathy, Doxorubicin, Doxorubicin Adverse Reaction
- Trial name
- NICBREASTRCT (NCT07897409)
- Testing
- Nicorandil Oral Tablet, Adriamycin (Doxorubicin)
- Where
- Egypt
- Volunteers
- 146 people
- Sponsor
- Universiti Sains Malaysia
Non-cystic Fibrosis Bronchiectasis
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis
The purpose of the study is to investigate the efficacy of galvokimig versus placebo on the time to the first pulmonary exacerbation in study participants with non-cystic fibrosis bronchiectasis (NCFB)
- Trial name
- ATMOS (NCT07720375)
- Testing
- Galvokimig
- Where
- 6 sites in United States
- Volunteers
- 300 people
- Sponsor
- UCB Biopharma SRL
Generalized Myasthenia Gravis
A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis
The purpose of the study is to assess the safety and tolerability of subcutaneous (sc) administration of rozanolixizumab in pediatric participants aged ≥2 to <18 years with generalized Myasthenia Gravis (gMG).
- Trial name
- roMyG (NCT06149559)
- Testing
- rozanolixizumab
- Where
- 9 sites in Italy, Japan and 2 more
- Volunteers
- 14 people
- Sponsor
- UCB Biopharma SRL
Gastrointestinal Tumors
A Study of SKB571 in Participants With Gastrointestinal Tumors
This is an open-label, multicenter, phase II study. The purpose of this study is to evaluate the safety, tolerability and preliminary anti-tumor activity of SKB571 in participants with gastrointestinal tumors.
- Trial name
- NCT07564466
- Testing
- SKB571 for injection
- Where
- 26 sites in China
- Volunteers
- 160 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Hepatocellular Carcinoma, Fibrolamellar Carcinoma
KAT-101 in Subjects With Hepatocellular Carcinoma (HCC)
NLP-KAT-101 is a Phase 1/2a dose escalation and expansion study to investigate the safety, tolerability, PK, and preliminary efficacy of oral + intratumoral (IT) KAT in subjects with HCC.
- Trial name
- NCT05603572
- Testing
- KAT-101, KAT-201
- Where
- South Korea
- Volunteers
- 1 people
- Sponsor
- Primocure Pharma
Solid Tumors
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer…
- Trial name
- NCT07415031
- Testing
- Adagrasib, Pembrolizumab, Cetuximab
- Where
- 101 sites in United States, Australia and 19 more
- Volunteers
- 170 people
- Sponsor
- Mirati Therapeutics Inc.
Atypical Endometrial Hyperplasia, Stage I Uterine Corpus Cancer AJCC v7
Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer
This phase II trial studies how well levonorgestrel-releasing intrauterine system works in treating patients with complex atypical hyperplasia or grade I endometrial cancer.
- Conditions
- Atypical Endometrial Hyperplasia, Stage I Uterine Corpus Cancer AJCC v7, Stage IA Uterine Corpus Cancer AJCC v7, Stage IB Uterine Corpus Cancer AJCC v7
- Trial name
- NCT00788671
- Testing
- Laboratory Biomarker Analysis, Levonorgestrel-Releasing Intrauterine System, Quality-of-Life Assessment
- Where
- 7 sites in United States
- Volunteers
- 69 people
- Sponsor
- M.D. Anderson Cancer Center
Adenocarcinoma, Prostate Cancer
Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance
Background: Prostate cancer is the second most common cause of cancer-related death among men in the United States. Early-stage, low-grade prostate cancer is managed with active monitoring.
- Conditions
- Adenocarcinoma, Prostate Cancer, Neoplasms, Carcinoma
- Trial name
- NCT07574541
- Testing
- TriAdeno vaccine, N-803
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)